FDA and industry offer compromise "least burdensome" paper
This article was originally published in Clinica
A small group from US industry and the FDA have agreed to a compromise proposal for dealing with the long-simmering dispute over how the agency should comply with the so-called "least burdensome" provision of the FDA Modernization Act of 1997 (FDAMA).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.